Lead Programs
| Programs | Indication | Discovery | Lead Optimization | IND-Enabling | Partner |
|---|---|---|---|---|---|
| STAT3 SH2 domain | |||||
| STAT3 SH2 domain | Inflammatory Diseases | Wholly-owned | |||
| STAT6 SH2 domain | |||||
| STAT6 SH2 domain | Inflammatory Diseases |  1 | |||
| Undisclosed SH2 domain | |||||
| Undisclosed SH2 domain | Inflammatory Diseases | Wholly-owned | |||
| Program | Indication | Stage | Partner |
|---|---|---|---|
| STAT3 SH2 domain | STAT3 SH2 domain | Inflammatory Diseases | IND-Enabling | Wholly-owned |
| STAT6 SH2 domain | STAT6 SH2 domain | Inflammatory Diseases | IND-Enabling | 1 |
| Undisclosed SH2 domain | Undisclosed SH2 domain | Inflammatory Diseases | Discovery | Wholly-owned |
1Recludix has the option to participate in an equal profit-sharing arrangement in the US, which includes certain co-promotion activities
STAT Inhibitors
Recludix is pursuing a novel approach to modulate the activity of the JAK/STAT family of pathways by targeting the downstream STAT proteins through inhibition of their SH2 domains. Targeting individual STAT proteins with highly selective inhibitors is expected to provide a more focused biological response than is observed with many JAK family kinase inhibitors. This may result in fewer side effects and the ability to more profoundly inhibit a specific pathway at well-tolerated doses.
Learn More
New Target Opportunities Identified with Platform
The opportunity to identify inhibitors of new targets with Recludix’s platform is vast. There are 120 SH2 domains identified in humans, and many targets that are known to play a role in disease pathology have SH2 domains. Additionally, the distinct features of Recludix’s integrated technology platform can be used to drug non-SH2 domain targets.